TABLE 4.
A summary of different approaches used to characterize nTyr using LC-MS/MS analysis
Methods used | Samples analyzed | # Sites | # Proteins | References |
---|---|---|---|---|
| ||||
WB 3-nTyr antibody | Human astrocytoma tissue | 20 | 18 | Peng et al. (2015) |
Precursor ion scanning | In vitro nitrated Bovine fibrinogen | 5 | - | Luo et al. (2015) |
Fluorogenic enrichment | Yeast lysate (in vivo) | 14 | 14 | Kang et al. (2015) |
Solid-phase chemical capture of aromatic amines | Peroxynitrite treated rat brain lysate | 244 | 144 | Nuriel et al. (2016) |
Protein-level IP anti-3-nTyr antibody | Secondhand smoke exposed rat’s brain lysate | - | 29 | Kobeissy et al. (2017) |
Peptide-level IP using anti-3-nTyr antibody | In vitro nitrated whole-cell lysate poly(I:C) treated mouse lung tissue | Cell lysate: 18811 Lung: 237 | Cell lysate: 907 Lung: 147 peptides | Zhao et al. (2017) |
2DGE, 3-nTyr WB, in-gel digestion, LC-MS/MS | In vitro nitrated beef heart mitochondria | 6 | 5 | Kohutiar et al. (2018) |
Filter-aided sample preparation (FASP) 1 targeted detection using Skyline | Peroxynitrite treated laminin | 148 | - | Lorentzen et al. (2019) |
2DGE and MALDI-TOF/TOF | Ischemia reperfused rat heart | - | 8 | Tatarkova et al. (2019) |
Anti-3-nTyr affinity, in-gel digestion, and LC-MS/MS analysis | In vitro nitrated S. meliloti proteins | 2 | 2 | Cazalé et al. (2020) |
3-nTyr antibody WB, in-gel digestion, and LC-MS/MS, PRM analysis using Skyline | Sodium nitroprusside treated CDKA;1 from maize embryo | 2 | - | Méndez et al. (2020) |
Untargeted LC-MS/MS analysis for treated SRM analysis for in vivo | Peroxynitrite treated and in vivo ischemic fibrinogen | Treated: 20 In vivo SRM: 9 | - | Medeiros et al. (2021) |
Result validation by comparing MS/MS spectra to synthetic nitropeptides | Hepatocyte nuclei from control and ethanol-exposed mice liver | 6 | 4 | Kriss et al. (2021) |
Abbreviation: CDKA, cyclin-dependent kinase A.